Tag: CRWD

BEKE Options Score Big Gains & More

Options Roundup:

As usual, there are several options ideas that we are actively tracking, in which we have been observing some excellent moves and opportunities for quick strike profits.

We’ve been on top of EXPI for a whole week now, and the stock continues to facilitate new highs in the plays that we’ve targeted in the options chain.Despite already posting some serious multibag moves, the bullish run continued early on in the session before a consolidation finally occurred. Here were the final figures on its impressive run as pertains to our tracked contract sets:

EXPI 03/19 $50-55 Calls
$50:  2.16-9.80 (+354%)
$52.50: 1.45-7.60 (+424%)
$55:  2.10-5.50 (+162%)
_____

BEKE and FUTU were the focus of our fresh options ideas in yesterday’s premarket report. They were earnings calendar plays and they both posted positive moves, with BEKE being the clear winner of the day:

BEKE Weekly $60-65 Calls 
$60:  3.60-12.05 (+235%)
$65:  1.19-7.60 (+539%)
_____

FUTU Weekly $157.50-162.50 Calls
$157.50: 8.52-12.10 (+42%)
$160: 7.28-11.00 (+51%)
$162.50: 7.60-9.80 (+29%)

Fresh Options Ideas:
CRWD Weekly $197.50-202.50 Calls
PDD Weekly $152.50-148 Puts

Extended Watchlist: 
HMNY, HPNN, PBYA, RDWD, SKPO, RCIT, NXGT, CPWY, CBDL, GBHL

PBIO News, Options Recaps

Pressure BioSciences, Inc. (OTCMKTS:PBIO)

First thing’s first today, we’ve got some fresh news out on PBIO that we wanted to pass along to our readers this morning. We sent out a report on PBIO yesterday that we would suggest you take a minute to go over now.

Today we are seeing the company release important info on the launch of its FDA-registered cannabis-enhanced, immune boosting prebiotic with proposed acquisition partner, Cannaworx

SOUTH EASTON, Mass., Dec. 4, 2020 /PRNewswire/ — Pressure BioSciences, Inc. (OTCMKTS: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that its proposed acquisition partner Cannaworx, Inc. has set December 2020 as the commercial launch date for its patented immune booster supplement: ImmunaZin™.  Cannaworx believes that post-launch, this product will be one of very few OTC (over the counter), FDA registered, hemp seed oil-enhanced supplements with an immune booster claim. (>>View Full PR via OTCMARKETS)

Successful Options Review

We also formulated some fresh options ideas for yesterday’s session in our premarket report, and found some solid success in the case of the CRWD and SPLK chains.

Here are the total ranges and possible profits that could have been seized: 

CRWD Weekly $155-162.50 Calls
$155: 3.92-11.25 (+187%)
$157.50: 3.00-8.87 (+197%)
$160: 2.14-7.75 (+262%)
$162.50: 1.63-5.75 (+253%)
_____

SPLK Weekly $170-160 Puts 
$170: 5.71-13.50 (+136%)
$165: 2.80-8.93 (+219%)
$160: 1.12-5.31 (+222%)
_____

Fresh Options Ideas:
DOCU Weekly $242.50-247.50 Calls 
ULTA Weekly $275-282.50 Calls 

PBIO Report, Options Ideas

Pressure BioSciences, Inc. (OTCMKTS:PBIO)

Pressure BioSciences is a company we’ve had on our watchlist for quite some time, with our first mention of the stock coming in the summer of 2019. We’re taking a renewed look at it now for a number of reasons, not least of which being the long term pattern of the chart.

If you glance at the three-year snapshot below (via OTCMARKETS.COM), a clear pattern can be easily spotted. The stock has an undeniable recorded history of consolidating in the winter months,only to spring back with vigor in the early portions of each New Year.

On its own, that interesting technical tendency would be enough to catch our attention, but Pressure BioSciences also seems to be planning for a big year of developments in 2021 as mentioned in the company’s Q3 Business Update released just a couple of weeks ago. According to the company, it expects the upcoming release of its Ultra Shear Technology™ in mid-2021 to drive notable growth and progress toward becoming profitable.

That only scratches the surface of PBIO’s products, projects and partnerships, which were expounded upon in the aforementioned Quarterly Update (>>View Now on OTCMARKETS.COM) Stay tuned for any further updates which we’ll be sure to pass along as expediently as possible!
_____

We also suggest our readers take a moment to view a real-time look at the short term PBIO chart . The stock is coming off of support at the 50DMA of 1,60, and it breached the 200DMA yesterday, closing just below it. If PBIO can break the 200DMA at 2.08 and hold above, our next key resistance points come at 2.50, 3.00, and 4.00-4.50. 


View PBIO Video Chart
______

For All Investor Inquiries on PBIO,Contact:
Gary Zwetchkenbaum, Plum Tree Consulting LLC
Email: gzplumtree@gmail.com
Phone: (516) 455-7662
Web: plumtreeconsultingllc.com 

SPDR S&P500 (ETF) SPY – Options Review

We also wanted to quickly highlight the SPY 12/02 $365-366 Calls which we signaled for a last minute idea in yesterday morning’s premarket report. We saw some pretty good intraday gains out of those targets.

SPY 12/02 $365-366 Calls
$365: .59-2.19 (+271%)
$366: .28-1.32 (+371%)
_____

Fresh Options Ideas:
SPLK Weekly $170-160 Puts
CRWD Weekly $155-162.50 Calls
SIG Weekly $30.50-32 Calls